Brighton Jones LLC Buys 3,807 Shares of Johnson & Johnson $JNJ

Brighton Jones LLC increased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 7.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 57,751 shares of the company’s stock after acquiring an additional 3,807 shares during the quarter. Brighton Jones LLC’s holdings in Johnson & Johnson were worth $8,822,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. GFG Capital LLC bought a new position in Johnson & Johnson during the second quarter worth $35,000. Stone House Investment Management LLC bought a new position in Johnson & Johnson during the first quarter worth $47,000. 1248 Management LLC bought a new position in Johnson & Johnson during the first quarter worth $48,000. von Borstel & Associates Inc. bought a new position in Johnson & Johnson during the first quarter worth $49,000. Finally, Harvest Fund Management Co. Ltd bought a new position in Johnson & Johnson during the first quarter worth $52,000. Institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on JNJ. Loop Capital set a $190.00 price target on shares of Johnson & Johnson in a report on Wednesday. JPMorgan Chase & Co. boosted their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a report on Tuesday, September 16th. Royal Bank Of Canada reissued an “outperform” rating and issued a $209.00 price target on shares of Johnson & Johnson in a report on Friday, October 10th. Wells Fargo & Company set a $212.00 price target on shares of Johnson & Johnson and gave the company an “overweight” rating in a report on Friday, October 3rd. Finally, Wall Street Zen upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $199.05.

Johnson & Johnson Stock Down 1.1%

Shares of NYSE:JNJ opened at $190.38 on Friday. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $194.48. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.07. The company’s fifty day moving average is $182.26 and its 200-day moving average is $166.25. The company has a market capitalization of $458.69 billion, a PE ratio of 18.38, a P/E/G ratio of 2.24 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The company had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be given a dividend of $1.30 per share. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.7%. Johnson & Johnson’s dividend payout ratio is 50.19%.

Insider Transactions at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is currently owned by company insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.